Literature DB >> 9168821

Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.

L Kjøller1, S M Kanse, T Kirkegaard, K W Rodenburg, E Rønne, S L Goodman, K T Preissner, L Ossowski, P A Andreasen.   

Abstract

Cell migration involves the integrins, their extracellular matrix ligands, and pericellular proteolytic enzyme systems. We have studied the role of plasminogen activator inhibitor-1 (PAI-1) in cell migration, using human amnion WISH cells and human epidermoid carcinoma HEp-2 cells in an assay measuring migration from microcarrier beads and a modified Boyden-chamber assay. Active, but not latent or reactive center-cleaved, PAI-1 inhibited migration. A PAI-1 mutant without ability to inhibit plasminogen activation was as active as wild-type PAI-1 as a migration inhibitor, showing that inhibition of plasminogen activation was not involved. PAI-1 specifically interfered with intergrin- and vitronectin-mediated migration: Migration onto vitronectin-coated but not onto fibronectin-coated surfaces was inhibited by PAI-1, a cyclic RGD peptide inhibited migration, and both cell lines expressed vitronectin-binding alpha v-integrins. In addition, active PAI-1, but not latent or reactive center-cleaved PAI-1, inhibited vitronectin binding to integrins in an in vitro binding assay, without affecting binding of fibronectin. Monoclonal antibodies against the urokinase receptor, another vitronectin binding protein, did not affect cell migration in the beads assay, while some inhibitory effect was observed in the Boyden-chamber assay. We conclude that PAI-1, independently of its role as a proteinase inhibitor, inhibits cell migration by competing for vitronectin binding to integrins, while the interference of PAI-1 with binding of vitronectin to the urokinase receptor may play a secondary role. These data define a novel function for the serpin PAI-1, enabling it to regulate cell migration over vitronectin-rich extracellular matrix in the body.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168821     DOI: 10.1006/excr.1997.3540

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  37 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  The shed ectodomain of type XIII collagen affects cell behaviour in a matrix-dependent manner.

Authors:  Marja-Riitta Väisänen; Timo Väisänen; Taina Pihlajaniemi
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

3.  Directional migration and transcriptional analysis of oligodendrocyte precursors subjected to stimulation of electrical signal.

Authors:  Yongchao Li; Xinkun Wang; Li Yao
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-12       Impact factor: 4.249

4.  Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.

Authors:  Hiroyuki Konno; Megumi Baba; Tuyoshi Shoji; Manabu Ohta; Shohati Suzuki; Satoshi Nakamura
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 5.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

6.  Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.

Authors:  Brandi R Whitley; Lea M Beaulieu; Jennifer C Carter; Frank C Church
Journal:  Gynecol Oncol       Date:  2006-10-30       Impact factor: 5.482

7.  Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing.

Authors:  François Maquerlot; Stephane Galiacy; Michel Malo; Christophe Guignabert; Daniel A Lawrence; Maria-Pia d'Ortho; Georgia Barlovatz-Meimon
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

8.  Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.

Authors:  Maria U Rømer; Lise Larsen; Hanne Offenberg; Nils Brünner; Ulrik A Lademann
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

9.  Antimetastatic potential of PAI-1-specific RNA aptamers.

Authors:  Charlene M Blake; Bruce A Sullenger; Daniel A Lawrence; Yolanda M Fortenberry
Journal:  Oligonucleotides       Date:  2009-06

Review 10.  Beyond oxygen: complex regulation and activity of hypoxia inducible factors in pregnancy.

Authors:  K G Pringle; K L Kind; A N Sferruzzi-Perri; J G Thompson; C T Roberts
Journal:  Hum Reprod Update       Date:  2009-11-19       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.